Tomorrow, 29th of November, Pasquale Piccolo
, Ivana Trapani
, Alessia Indrieri
and Nicola Brunetti-Pierri
will have their speeches into the webinar "Advancements in Gene Therapy Applications: From HSCs to Liver, Retinal and Mitochondrial Diseases" organized by Miltenyi Biotec
Two days to explore how gene therapy is revolutionizing medicine for genetic diseases and rare disorders. Covering all development stages from basic research to clinical applications, the discussion will include hematopoietic stem cells, research on liver diseases, retinal disorders, and mitochondrial conditions.
"Join our community of experts in cell and gene therapy. When you're working at the cutting edge of cell and gene therapy, it can be difficult to find opportunities to exchange ideas with other experts in your field. That's why we put together a series of meetings to bring together scientists and clinicians who can learn from each other in a friendly setting. Sign up for the upcoming event “Advancements in gene therapy applications. From HSCs to liver, retinal, and mitochondrial diseases”. This is slogan that Miltenyi has chosen for this event
that will held also TIGET researchers on the 28th of November.
Timeline of the day
About Miltenyi Biotec
Miltenyi Biotec was founded in 1989 based on the invention of MACS® Technology. Their technological solutions have made an important contribution to the advancement of biomedical science ever since. Today their more than 18,000 products play a vital role in paving the way for the medicine of tomorrow. They offer comprehensive solutions for our customers’ workflows, from basic research to translation into clinical applications.
Their integrated technologies span a broad range of applications, from cellular research to genetic sequencing, high-content imaging, and commercial-scale manufacturing of cellular therapies.They are scientists themselves and share their customers’ mindset. They are passionate about unraveling nature’s complexity. This is what drives them research and inspires our products.